A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])
Latest Information Update: 20 Jan 2023
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib
- Indications Adenocarcinoma; Bladder cancer; Cholangiocarcinoma; Lung cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Skin cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Dec 2022 Results assessing assesses the safety of LEN-based treatment (including LEN+dexamethasone [Rd] and Rd+bortezomib [RVd]) or non-LEN treatment (including bortezomib+melphalan/prednisone [VMP]) in patients with TNE NDMM presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 27 May 2022 Planned End Date changed from 31 Mar 2025 to 13 Jan 2026.
- 27 May 2022 Planned primary completion date changed from 31 Mar 2025 to 13 Jul 2024.